Who We Are
How can we do more for our patients? Everything at Takeda starts with this question. Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in our distinguished history in Japan since 1781.
Opened in July 2018, Takeda’s Global Headquarters in Nihonbashi, Tokyo, serves as the head office for its operations worldwide. The building’s interior was designed by Kashiwa Sato, one of the world’s leading creative directors, and expresses the essence of Takeda’s values and its core commitment to always put patients first.
As a global biopharmaceutical leader, it’s important to have a strong corporate philosophy. Since our founding in 1781, we have cultivated our corporate philosophy’s core components, which today we refer to as our Mission, Vision, Values and Strategic Roadmap.
Takeda fosters a collaborative and stimulating work environment driven by integrity and filled with opportunities to make a difference in people’s lives. Across our company, our employees bring together diverse strengths that together create a stronger whole.
What is Hunter Syndrome?
In Hunter syndrome, GAGs build up in cells throughout the body due to a deficiency or absence of the enzyme iduronate-2-sulfatase (I2S). This buildup interferes with the way certain cells and organs in the body function and leads to a number of serious symptoms. As the buildup of GAGs continues throughout the cells of the body, signs of Hunter syndrome become more visible. Physical manifestations for some people with Hunter syndrome include distinct facial features, a large head, and an enlarged abdomen. People with Hunter syndrome may also experience hearing loss, thickening of the heart valves leading to a decline in cardiac function, obstructive airway disease, sleep apnea, and enlargement of the liver and spleen. Range of motion and mobility may also be affected. In some cases of Hunter syndrome, central nervous system involvement leads to developmental delays and nervous system problems. Not all people with Hunter syndrome are affected by the disease in exactly the same way, and the rate of symptom progression varies widely. However, Hunter syndrome is progressive and life-limiting.
Two of the most significant areas of variability concern the degree of mental impairment and expected life span. Some people who have Hunter syndrome are not mentally impaired and live into their 20s or 30s; there are occasional reports of people who have lived into their 50s or 60s, and many adults are actively employed. In contrast, others with Hunter syndrome develop severe mental impairment and have shorter life expectancies.
Meet Aiden and AJ
Hunter syndrome, also known as Mucopolysaccharidosis II (MPS II) is a progressive, genetic disease. Learning your child has Hunter syndrome poses a whole new set of circumstances for a family to adjust to.
Meet Toni-Ann, mother of Aiden and AJ. Both Aiden and AJ were diagnosed with Hunter syndrome after seeing a geneticist recommended by their pediatrician. In this interview, Toni-Ann outlines her experience raising two boys with Hunter syndrome. She describes the signs and symptoms that led to the boy’s initial diagnoses, coming to terms with their diagnoses and the difficulties they face as children in society.
LSD Regional Business Manager, Philadelphia
Rare Diseases Business Unit
Takeda Pharmaceutical Company Limited
Shire is now part of Takeda
Mobile +1 267-250-7693